Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 140 participants.

Also called NCT05920889

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 140 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05920889
Other papers using this trial's data
  • Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial Nature communications, 2025-12-14 DOI, PubMed 41392086, PMC12717234 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China, Hong Kong SAR China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05920889. Randomized; no masking; primary purpose treatment. Start 2023-08-01 (actual); primary completion 2024-10-25 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies
Acronym
GALLOP
Condition
Stroke
Condition
Stroke, Acute
Condition
Stroke, Ischemic
Condition
Brain Diseases
Intervention (Drug)
Semaglutide
Lead sponsor
Chinese University of Hong Kong (class: other)
Collaborator
Linyi People's Hospital (class: other)

Record details

Record id
cardio:ct-nct05920889
Content hash
a1b44c1cf300841fbe973701f809187092d9fdca139e9c42aea03da615cc3788